CANADIAN PEDIATRIC PULMONARY ARTERIAL HYPERTENSION (PAH) REGISTRY
نویسندگان
چکیده
منابع مشابه
Pulmonary Arterial Hypertension (PAH) Panel
The PAH Panel provides a high quality read-out of all genes with well-established association to pulmonary arterial hypertension. Our OS-SeqTM technology provides high coverage clinical grade sequencing and enables reliable diagnostics for PAH patients with significantly lower costs and faster turnaround time (basic service TAT 21 days and Express service TAT 7-10 days). The PAH Panel has under...
متن کاملIranian Pulmonary Arterial Hypertension Registry
BACKGROUND Idiopathic pulmonary arterial hypertension (IPAH) is a fatal disorder with a prevalence of 8.6 per million. We introduce a registry website for IPAH and PAH patients ( www.IPAH.ir) for access and efficient delivery of government-aided and subsidized antihypertensive medications. MATERIALS AND METHODS The IPAH registry was opened in November 2009. Information of IPAH and PAH patient...
متن کاملPulmonary Hypertension Registry: a 10-Year Experience
Background: Pulmonary Arterial Hypertension (PAH), a fatal orphan disease, is defined as increased mean Pulmonary Arterial Pressure (mPAP) above 25 mm/Hg, Pulmonary Capillary Wedge Pressure (PCWP) below 15 mm/Hg, and pulmonary vascular Resistance over 3 Wood Unit (WU). Although Pulmonary Hypertension (PH) is a relatively prevalent disease, the idiopathic form (iPAH) is a rare disease with a pre...
متن کاملThe Importance of Electrocardiography in Pediatric Patients with Pulmonary Arterial Hypertension in Follow- up
Background: Right Ventricular (RV) hypertrophy is an adaptive response to chronic RV pressure overload in patients with pulmonary hypertension. We investigated the relationships between RV hypertrophy indicators, including electrocardiography, the percentage oxygen saturation (SaO2%), body mass index (BMI), and blood uric acid levels in patients with...
متن کاملRiociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
Clinical background Despite recent advances, the prognosis for patients with pulmonary hypertension remains poor. Riociguat (BAY 63-2521) is a novel oral stimulator of the nitric oxide (NO) receptor soluble guanylate cyclase, and synergizes with low levels of bioavailable NO. Its safety and efficacy in dose titration were studied in patients with PAH (n = 33) or CTEPH (n = 42) in this multicent...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian Journal of Cardiology
سال: 2015
ISSN: 0828-282X
DOI: 10.1016/j.cjca.2015.07.400